FDA Approval Insights: Cilta-Cel in R/R Myeloma After at Least 1 Prior Line of Therapy
Season 10, Episode 27, Apr 22, 06:15 PM
Dr Usmani details the FDA approval of cilta-cel for patients with relapsed/refractory multiple myeloma who have received at least 1 prior line of therapy.